Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimerâ€™s disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/07/26	SEK 0.0310	-3.12%	3,704,320
14/07/26	SEK 0.0320	-5.33%	873,625
13/07/26	SEK 0.0338	+5.62%	158,541
10/07/26	SEK 0.0320	-2.44%	4,433,745
09/07/26	SEK 0.0328	-7.34%	6,454,649

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Stockholm Other stock markets 20:00:00 15/07/2026 +04			5-day change	1st Jan Change
0.0310 ^SEK	-3.12%		-12.43%	+13.14%

05-29	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-29	Gabather AB Auditor Raises 'Going Concern' Doubt	CI

Market Cap	18.93M 1.97M 1.72M 1.59M 1.46M 2.76M 189M 2.81M 7.43M 92.44M 7.38M 7.22M 319M	P/E 2024	-1.07x	P/E 2025	-1.13x
Enterprise Value	15.78M 1.64M 1.43M 1.32M 1.22M 2.3M 158M 2.34M 6.19M 77.09M 6.16M 6.02M 266M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	88.76%	Yield 2024 *	-	Yield 2025	-

05-29	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-29	Gabather AB Auditor Raises 'Going Concern' Doubt	CI
04-08	Gabather submits preliminary patent application	RE
03-18	Gabather board decides on directed share issue	RE
02-27	Gabather AB Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	Gabather carries out directed issue	RE
12-03	Gabather exercises warrants, raises SEK 4.35 million	RE
11-27	Gabather Q3 operating loss SEK 1.5 mln	RE
11-27	Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-24	Gabather to file provisional patent application with United States Patent and Trademark Office	RE
09/09/25	Gabather CFO Kristofer Svensson to resign	RE
28/08/25	Gabather Q2 operating loss SEK 1.3 mln	RE
28/08/25	Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

06-02	Gabather: Phase II finally activated	AQ
05-08	Gabather: Starting phase II clinical trial	AQ
03-19	Gabather: Key shareholders show support	AQ
12-01	Gabather: Eager to start the TOTEMS study	AQ
01/09/25	Gabather: TOTEMS-study delayed, not derailed	AQ

Gabather AB Stock

Stocks

GABA

SE0010869552

Biotechnology & Medical Research

Valuation: Gabather AB

Chart: Gabather AB

Latest news : Gabather AB

Press Releases: Gabather AB

Quotes and Performance

Course Extremes

Managers and Directors: Gabather AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-3.13%
1 week	-12.43%
Current month	-15.76%
1 month	-20.10%
3 months	-12.43%
6 months	+9.15%
Current year	+13.14%

1 week	0.03	0.04
1 month	0.03	0.04
Current year	0.02	0.1
1 year	0.02	0.13
3 years	0.02	4.2
5 years	0.02	7.2
10 years	0.02	65.6

Manager	Title	Age	Since
Michael Robin Witt CEO	Chief Executive Officer	-	01/10/2018
Christine Natasha Ryan COO	Chief Operating Officer	-	01/01/2018
Stefan Rehnmark CTO	Chief Tech/Sci/R&D Officer	-	01/01/2018

Director	Title	Age	Since
Michael Robin Witt BRD	Director/Board Member	-	01/09/2014
Bert Roland Kari Junno BRD	Director/Board Member	60	03/11/2014
Theresa Comiskey Olsen BRD	Director/Board Member	63	30/06/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GABATHER AB	-3.12%	-12.43%	-32.02%	-98.89%	2.03M
ARGENX SE	-1.39%	-6.15%	+56.05%	+71.53%	54.49B
WUXI APPTEC CO., LTD.	+3.13%	+11.16%	+67.30%	+94.35%	55.93B
INSMED INCORPORATED	-0.27%	-5.77%	+6.75%	+430.48%	23.87B
BIONTECH SE	+1.76%	-1.65%	-16.86%	-14.20%	22.86B
WUXI BIOLOGICS (CAYMAN) INC.	+3.51%	+7.50%	+47.81%	-3.33%	20B
GENMAB A/S	+1.94%	+0.21%	+39.31%	-29.41%	17.48B
PHARMAESSENTIA CORPORATION	+10.00%	-2.06%	+210.10%	+370.99%	15.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.69%	+4.38%	+56.51%	+712.88%	15.19B
EXELIXIS, INC.	-0.39%	-1.00%	+26.08%	+189.47%	14.02B
Average	+2.29%	-0.76%	+46.10%	+172.39%	23.92B
Weighted average by Cap.	+2.10%	+0.47%	+53.07%	+157.76%

	2024	2025
Net sales	-	-
Net income	-7.75M -805K -704K -649K -597K -1.13M -77.48M -1.15M -3.04M -37.87M -3.02M -2.96M -131M	-4.65M -483K -422K -390K -358K -679K -46.49M -690K -1.83M -22.72M -1.81M -1.77M -78.32M
Net Debt	-878K -91.19K -79.72K -73.54K -67.61K -128K -8.77M -130K -345K -4.29M -342K -335K -14.78M	-3.14M -326K -285K -263K -242K -459K -31.41M -466K -1.23M -15.35M -1.23M -1.2M -52.91M